Mirfazaelian et al. developed a physiologically based pharmacokinetic (PBPK) model for the pyrethroid pesticide deltamethrin in the rat. This model describes gastrointestinal (GI) tract absorption as a saturable process mediated by phase III efflux transporters which pump deltamethrin out of the intestinal enterocytes into the GI tract lumen, resulting in minimal net absorption at low concentrations and increasing absorption at higher concentrations. In the present study, the dose dependency in absorption of deltamethrin was examined in male Long Evans rats using po exposures predicted by the Mirfazaelian model to yield different po bioavailability values. No difference in the bioavailability from single po doses of 0.3 and 3.0 mg/kg deltamethrin was observed. Based on this finding, the Mirfazaelian PBPK model was modified to exclude a saturable absorption process. Other changes to the Mirfazaelian model included describing all tissue compartments with diffusion-limited kinetics and a single blood compartment. These changes improved model predictions of deltamethrin tissue concentration data from the present study and the literature. The rat model was then scaled to humans. The model predicted a twofold greater peak deltamethrin brain concentration and threefold greater area under the curve (AUC 0-48 h ) for humans following an po exposure of 1 mg/kg. Based on this model, humans would have greater distribution of deltamethrin to the brain for the same administered po dose compared to rats. The relative sensitivity to deltamethrin between rats and humans depends on both pharmacokinetic and pharmacodynamic differences. Species differences in the pharmacodynamic responses to deltamethrin between rats and humans remain uncharacterized.
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Deltamethrin is a pyrethroid pesticide used in the protection of a wide range of commercial crops, ornamentals, and trees. Deltamethrin is also used in domestic insect control and as an ectoparasiticide in both human and veterinary medicine. Exposure to deltamethrin occurs through occupational, residential, medicinal, and dietary exposures (Heudorf and Angerer 2001; Schettgen et al., 2002; Smith et al., 2002; Zhang et al., 1991) . Deltamethrin induces neurotoxicity by slowing the opening and closing of voltage-gated sodium channels, although voltage-gated calcium channels, chloride channels, or other mechanisms may also play a role (Shafer and Meyer, 2004) . Acute pyrethroid poisoning in humans induces paresthesiae from skin exposure and sore throat, nausea, vomiting, and abdominal pain from ingestion. Neurological effects include dizziness, headache, fatigue, blurred vision, coma, and convulsions (Bradberry et al., 2005) . The effects in humans are similar (He et al., 1989) to those observed in laboratory animals (Soderlund et al., 2002) , suggesting similar modes of action across species. Because of the increasing use of these pesticides, a better understanding of the human health risks associated with pyrethroid exposure is important.
There are qualitative and quantitative differences in the metabolism of deltamethrin between rats and humans (Godin et al., 2006 (Godin et al., , 2007 . In vitro hepatic microsomal metabolism studies suggest that the intrinsic hepatic clearance of deltamethrin is nearly twice as rapid in humans compared to rats (Godin et al., 2006 (Godin et al., , 2007 . Furthermore, hydrolysis is the predominant route of in vitro hepatic metabolism of deltamethrin in humans, while in rats, oxidative metabolism predominates (Godin et al., 2006) . Carboxylesterases that metabolize deltamethrin in rat serum Godin et al., 2007) are absent in human serum Godin et al., 2007) . These differences in metabolism may influence the extrapolation of exposure and internal dose across species and alter the relative potency of deltamethrin between humans and experimental animals.
Physiologically based pharmacokinetic (PBPK) models can provide a framework for extrapolating rodent toxicity data to humans (Andersen, 2003) . PBPK models are mathematical descriptions of the physiological, biochemical, and physicalchemical properties involved in the absorption, distribution, metabolism, and elimination of a chemical from the body. Mirfazaelian et al. (2006) developed a PBPK model for orally absorbed deltamethrin in the adult male Sprague-Dawley rat. A unique component of the model is its description of deltamethrin absorption in the gut. Based on literature data (Bosch, 1990; Ruzo et al., 1978) and their modeling results, Mirfazaelian et al. (2006) proposed that deltamethrin is a substrate for phase III xenobiotic efflux transporters that line the gastrointestinal (GI) tract. As such, efflux transporters would pump deltamethrin out of the intestinal enterocytes into the GI tract lumen and effectively reduce absorption at low concentrations. High concentrations of deltamethrin would saturate the efflux transporters, resulting in greater absorption at higher deltamethrin exposures. However, a more complete analysis of the available data in the literature on the absorption of deltamethrin following po exposures suggests some inconsistencies with this hypothesis (Bosch, 1990; Ruzo et al., 1978) (Fig. 1) . Examination of all the fecal excretion data for deltamethrin suggests that~13-37% of an administered po dose (0.55-5.5 mg/kg) is not absorbed and directly eliminated in the feces. The extent of biliary elimination of deltamethrin is not known, but studies by Crawford et al. (1981a,b) with cypermethrin in the rat indicate that < 2% of the dose was eliminated by this route with only conjugated metabolites detected. Thus, the evidence of a dose-dependent relationship between absorption and administered dose is limited (Fig. 1) .
The model of Mirfazaelian et al. (2006) describes the fat and slowly perfused tissues as diffusion limited while using flow-limited descriptions for the brain, liver, and richly perfused compartments. While the liver is the primary organ for metabolic clearance of deltamethrin , Godin et al., 2006 Crow et al., 2007) , data on liver concentrations following deltamethrin exposures are limited to two studies using iv administration Rickard, 1981, 1982) . These studies report only total radioactivity in the liver, which limits the utility of these data in model development because radioactivity derived from deltamethrin or metabolites were not differentiated.
In the present study, po bioavailability and disposition studies of deltamethrin were performed to address data gaps and uncertainties in the PBPK model. Using these new data and the model of Mirfazaelian et al. (2006) as a starting point, a refined PBPK model for deltamethrin in rats was developed and compared to the previous model using the discrepancy index of Krishnan et al. (1995) . This refined model was then used as the basis for the development of a human PBPK model to examine the influence of the species differences in the metabolism of deltamethrin on the relationship between exposure and internal tissue concentrations.
MATERIALS AND METHODS
Chemicals. Deltamethrin (98.9% purity) ((aS)-cyano-3-phenoxybenzyl (1R, 3R)-cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylate) was a gift from Bayer Crop Sciences (Research Triangle Park, NC). Labeled cisand trans-permethrin (phenoxy-13 C 6 ) (99% purity) were purchased from Cambridge Isotope Laboratories (Andover, MA). Analytical grade Chromasolv acetonitrile and methanol for liquid chromatography/mass spectrometry (LC/MS) applications were from Riedel-de Haën (Seelze, Germany). Solvents, including acetone, hexanes (Fisher Scientific, Pittsburgh, PA), and methanol (VWR, West Chester, PA), were pesticide grade. Corn oil, glycerol formal, heparin, dextrose, and saline were purchased from Fisher Scientific. Unless otherwise specified, all chemicals were of the highest grade commercially available.
Animals. All animal procedures were approved by the National Health and Environmental Effects Research Laboratory Institutional Animal Care and Use Committee. Male Long Evans rats (~70 days old) were obtained from Charles River Laboratory (Raleigh, NC) with or without jugular vein catheters. Animals were allowed to acclimate for a minimum of 4 days in an Association for Assessment and Accreditation of Laboratory Animal Care approved animal facility prior to their use. Two animals were housed per plastic cage (45 3 24 3 20 cm) with heat-treated pine shavings bedding (Northeastern Products, Inc., Warrensburg, NY). Cannulated animals for bioavailability studies were housed one animal per cage. Animals were maintained at 21°C ± 2°C, 50 ± 10% humidity, and a photoperiod of 12L:12D (0600 h-1800 h). Food (Purina Rodent Chow 5001, Barnes Supply Co., Durham, NC) and tap water were provided ad libitum. Animals were exposed to deltamethrin in either glycerol formal (iv) or corn oil at 1 ml/kg dosing volume. Doses included a 1-mg/kg iv dose and 0.3-and 3.0-mg/kg po doses via gavage. The Mirfazaelian model predicts po absorption of~40 and 90% at the 0.3-and 3-mg/kg po doses, respectively. The 3.0-mg/kg dose produces a 30% decrease in motor activity, while the 0.3-mg/kg dose produces no adverse behavioral toxicity (Wolansky et al., 2006) .
Po bioavailability study and blood collection. Cannulated rats were exposed orally via gavage (0.3 and 3.0 mg/kg deltamethrin) or iv (1 mg/kg FIG. 1. Fecal excretion of deltamethrin after po administration in the rat. Individual data points from Ruzo et al., 1978 (; ) , Bosch, 1990 (d [ 14 C]benzyllabeled deltamethrin), and Bosch, 1990 ( [ deltamethrin) through the indwelling jugular vein catheter. There were four animals for each dose. Serial blood samples were taken at time points ranging from 5 min to 36 h postdosing. At each time point, 300 ll aliquots of blood were removed via the catheter and immediately flash frozen in liquid nitrogen. Between each sampling time, catheters were rinsed with 300 ll saline and filled with a void volume of heparanized dextrose as a lock solution to maintain catheter patency.
Deltamethrin disposition study. A second group of rats was exposed via gavage to 0.3 or 3.0 mg/kg deltamethrin in corn oil at a volume of 1 ml/kg. At time points ranging from 1 to 48 h, animals were sacrificed by cardiac puncture under CO 2 -induced anesthesia. Blood, brain, liver, and fat samples were immediately removed, weighed, and flash frozen in liquid nitrogen. Tissue samples were stored at À80°C until residue analysis was performed. For each dose, there were four rats per time point.
Tissue extraction. Frozen brain, liver, and fat were pulverized in a Spex CertiPrep 6850 freezer/mill (Metuchen, NJ) to form a fine homogeneous tissue powder. Aliquots of thawed blood (0.3 ml) and pulverized tissue (300-500 mg) were vortex extracted with 20:80 acetone:hexane. Twenty-five microliters of 6lM labeled trans-permethrin (phenoxy-13 C 6 ) in acetone was added prior to extraction as a surrogate of recovery. Samples were vortexed for 10 min in 16 3 100-mm culture tubes with 5 ml solvent and centrifuged at 4000 3 g for 10 min. The organic layer was collected. This process was repeated twice more with 3 ml solvent, combining organic fractions of each extraction. Pyrethroid-containing organic fractions were dried under nitrogen and reconstituted in 1 ml hexane.
Reconstituted blood and brain extracts underwent solid phase extraction (SPE) using hexane (5 ml)-rinsed Sep-pak 500 mg silica SPE columns (Waters, Inc., Milford, MA). The solid phase cleanup was automated using a RapidTrace SPE Workstation (Hopkinton, MA). SPE columns were washed with 5 ml hexane prior to sample loading. Analytes were eluted with 5 ml 94:6 hexane:ethyl acetate. Column eluants were dried under a stream of nitrogen and reconstituted in 1 ml of 90:10 methanol:water with 25 ll of 6lM cis-permethrin (phenoxy-13 C 6 ) added as an internal standard of instrument efficiency for LC/ MS analysis.
Reconstituted liver and fat extracts were loaded onto silica-containing analytical gel permeation chromatography preparatory columns with a 70% ethyl acetate and 30% cyclopentane mobile phase at 5 ml/min. A 25 ml fraction containing the pyrethroids was collected with a fraction collector and then dried under a stream of nitrogen. Samples were reconstituted in 3 ml hexane. Liquidliquid extraction was conducted with equal volumes of the hexane extracts and hexane-saturated acetonitrile. The liquid-liquid extraction was repeated three times, and the acetonitrile fractions were combined, dried under a stream of nitrogen, and reconstituted in 1 ml of 90:10 methanol:water with 25 ll of 6lM labeled cis-permethrin (phenoxy-13 C 6 ) added as an internal standard of instrument efficiency for LC/MS analysis.
Residue determination. An Agilent (Palo Alto, CA) 1100 series LC/mass spectometer detector VL ion trap mass spectrometer and Hewlett Packard Chemstation software were used for identification and quantification of deltamethrin as previously described by Godin et al. (2006) with minor modifications. Briefly, isocratic elution of chemicals was accomplished with an Agilent Zorbax Eclipse XDB-C18 column (4.6 3 100 mm, 3.5 lm pore size) and XDB C-18 guard column with a mobile phase of 90% methanol and 10% 5mM ammonium formate at a flow rate of 0.5 ml/min. Deltamethrin identification and quantification was accomplished by fragmentation of the ammonium-adducted ion [M þ NH 4 ] þ (m/z 523) to produce the parent ion
Deltamethrin was quantified using at least a five-point calibration curve, prepared in tissue appropriate matrix, containing 13 C 6 -cispermethrin internal standard. Residue concentrations were determined by the ratio of internal standard response to the analyte response. Calibration standards ranged from 1 to 500 ng/ml. Method limits of deltamethrin quantification werẽ 5 ng/ml or g for blood and brain, respectively, and 10 ng/g for liver and fat. Surrogate (trans-permethrin phenoxy 13 C 6 ) recovery values of 80-120% of expected were deemed acceptable. Samples with surrogate recoveries above or below the acceptable range were reanalyzed. Bioavailability analysis. Bioavailability was calculated from the experimental data of the 0.3-and 3.0-mg/kg po doses compared to the 1-mg/kg iv dose using Equation 1.
Bioavailability ¼ (AUC po /AUC iv ) 3 (dose iv /dose po ) 3 100, (1) where AUC po represents the area under the curve to infinity for the blood after an po dose (dose po ) and AUC iv represents the AUC for the blood to infinity after an iv dose (dose iv ). The trapezoidal rule was used to calculate the AUC values. The difference in the bioavailability between dose levels was evaluated using a Student's t-test. The level of significance was p < 0.05.
PBPK modeling. All PBPK modeling employed AcslXtreme software version 2.3.0.12 (The Aegis Technologies Group Inc., Huntsville, AL). An initial PBPK model for deltamethrin was developed in AcslXtreme based on the model of Mirfazaelian et al. (2006) . Figure 2 depicts the general model structure. Tissue compartments included brain (target tissue), liver (metabolic compartment), fat, and slowly and richly perfused tissues. A series of modifications to the Mirfazaelian model were developed and evaluated for their ability to describe data using the discrepancy index of Krishnan et al. (1995) .
The Supplementary materials describe stepwise evolution of the model, while the main text focuses on the final version. Significant changes between the Mirfazaelian model and the present model focus on the descriptions of the GI tract, blood, liver, and the application of the diffusion limitations for describing the distribution of deltamethrin. The Mirfazaelian model describes absorption as a saturable process that includes an explicit description of the stomach with a gastric juice component, an intestinal lumen, and GI compartments. Absorption occurred from both the stomach and the intestinal lumen into the GI compartment and entered the portal vein into the liver. In the present model, the description of the deltamethrin absorption is based on a chlorpyrifos PBPK model (Timchalk et al., 2002) with the exception of the rate constant for stomach absorption (K s ), which was removed. Initial results and optimization of K s resulted in values close to zero, which did not influence peak and time to peak blood concentrations. Eliminating the saturable absorption process, described in the Mirfazaelian model, was based on the available published data ( Fig. 1 ) and in vivo data from the manuscript (see Results section). Fecal excretion was described as a first-order process resulting in excretion of 25% of the po dose, which is approximately the median of the range of reported values in the literature (Bosch, 1990; Ruzo et al., 1978) . Unlike the blood compartment of the Mirfazaelian model, which consisted of plasma and erythrocyte compartments, a single blood compartment was used in the present model.
The effects of the stepwise changes to the model on the overall difference between the predicted values and the experimental data were evaluated using the discrepancy index (Krishnan et al., 1995) and are presented in full in the Supplementary material. Simplifying the Mirfazaelian model by lumping the plasma and RBC into a whole-blood compartment, removing the GI tissue compartment, eliminating absorption from the stomach lumen, and describing the fecal elimination as a rate constant had minimal effect on the model predictions. Specifying all compartments as diffusion limited, applying the metabolic constants from the in vitro studies of Godin et al. (2006) , and optimizing the partition coefficients (P T ) and permeability coefficients to data from the present study decreased the discrepancy index compared to the Mirfazaelian model from 54.2 to 46.7. Evaluating the model against data from Gray and Rickard (1982) , Mirfazaelian et al. (2006) , and data presented in this publication decreases the discrepancy index to 35.7. Based on the overall decrease in the discrepancy index from 54.2 to 35.7, changes made to the Mirfazaelian model were retained and are presented in the Results section.
Physiological parameters were determined from the available literature (Table 1) . Experimental estimates of the P T for each tissue compartment were unavailable and were calculated by the computational approach of Poulin and Theil (2000) . This method is based on tissue composition and describes the expected solubility of the chemical in each tissue compartment (Table 1) . Metabolism parameters for liver and blood clearance were based on the in vitro data of Godin et al. (2006 Godin et al. ( , 2007 . Twelve model parameters were optimized with AcslXtreme OpStat to the 3.0-mg/kg po data from the present study.
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Model parameters were estimated with the heteroscedascity parameter (c) equal to 2 as data error was approximately proportional to concentration (constant coefficient of variation). Diffusion-limited model optimization. The calculated tissue P T and the permeability area coefficients (PA T C) for richly and slowly perfused compartments were optimized to the 1.0-mg/kg iv data in order to remove po absorption as a confounding factor. Blood, liver, brain, and fat P T and PA T C and the intestinal uptake rate constant (K i ) were then optimized to fit the respective tissue concentration data from the 3.0-mg/kg po dose. Optimization of the po absorption parameters resulted in~27% of the po dose excreted in the feces, consistent with literature estimates. While the resulting parameters for the fat compartment fit the data from the current studies out through 48 h, the fat parameters required visual fit as the optimization routine underestimated the later time points from two literature studies (Mirfazaelian et al., 2006; Ruzo et al., 1978) . Literature data included time points at 8, 14, and 21 days postexposure, whereas the present study only included time points out to 48 h.
Sensitivity analysis. Sensitivity analysis was conducted on the rat and human models utilizing the OpStat sensitivity analysis software in AcslXtreme. Model parameters were changed individually by 0.1% to assess their impact on model prediction of peak blood and brain concentrations. Sensitivity coefficients were normalized to both the observed variable and the parameters being examined. The normalized sensitivity coefficient (NSC) values were determined by the following equation:
where m is the response variable (e.g., peak arterial blood concentration), DM the change in response variable, p the value of the parameter, and Dp is the change in the parameter value. Each parameter was increased by 0.1% (Dp/p ¼ 0.001), and the NSCs were computed for a simulation of 1.0-mg/kg po dose for 48 h for both rats and humans.
Extrapolation from rat to human PBPK model. The rat PBPK model was extrapolated to a human PBPK model by incorporating data from the literature on human physiological parameters for cardiac output, blood flows to individual tissues, volume of individual tissues, and blood volume fractions for individual tissues (Table 1) . Hepatic clearance rate (K cl ) was obtained from in vitro microsomal metabolism studies by Godin et al. (2006) . All other model parameters were held constant from the rat model except for the blood clearance parameter, which was set to zero. The serum of rats, but not humans, contains significant esterases that metabolize deltamethrin (Godin et al., 2007) ; thus a blood metabolic clearance rate is included in the rodent but not the human model. Table 1 .
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RESULTS
Bioavailability Study
Blood concentration data after iv dosing of 1 mg/kg deltamethrin in glycerol formal and 0.3 and 3.0 mg/kg po doses in corn oil were used to assess the po bioavailability of deltamethrin (Figs. 3A-C) . The area under the concentration curves for the 1.0-mg/kg iv, 3.0-mg/kg po, and 0.3-mg/kg po were 2.2 ± 0.6, 1.9 ± 0.5, and 0.17 ± 0.03 lg/ml h (mean ± SD), respectively. The po bioavailability of deltamethrin was not significantly different (p > 0.05) between the 0.3-mg/kg (25 ± 5.1%) and the 3.0-mg/kg doses (28.0 ± 7.0%).
Simulation of Blood Concentrations
A biphasic decline in deltamethrin concentrations in the blood (Fig. 3A inset) was observed in the first 4 h after injection of a bolus dose, similar to the data of Gray and Rickard (1982) (Fig. 4 ). The present model accurately simulated the shape (Figs. 3B and 3C ). Deltamethrin was rapidly absorbed after po exposure with peak blood concentrations 1-2 h postexposure. The model estimated peak concentration at~1.5 h. The model accurately simulated the rapid rise in blood concentration, time to peak, peak concentration, and the rapid elimination of deltamethrin from the blood at both doses (Figs. 3B and 3C ).
Simulation of Brain Concentrations
Brain concentrations of deltamethrin were at or below limits of detection in the 0.3-mg/kg exposure group at all time points examined. Brain concentration of deltamethrin peaked at 3 h in animals exposed to 3 mg/kg. The use of a computationally derived brain P T resulted in overestimation of brain concentrations of deltamethrin (simulation not shown). Decreasing the brain P T by nearly 300-fold was necessary for more accurate simulations of the magnitude of the brain concentration-time course data. Changing the PA T C resulted in changes in the shape of the tissue concentration-time course profile. Thus, this parameter was not changed from its optimized value. The model simulated peak brain concentrations at 2.6 h and accurately fits declining concentrations of deltamethrin (Fig. 5) . The delay in time of peak deltamethrin brain concentration relative to the time of peak blood concentrations is an indication that the diffusion-limited description of the brain compartment may be appropriate. While there is a rapid decline in the brain concentration with time, this does not appear mediated by metabolism (Godin et al., 2007) . 
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Simulation of Liver Concentrations after Po Exposure
The concentration of deltamethrin in the liver rose rapidly after an po dose of 3.0 mg/kg, peaking 1-2 h after exposure and decreasing to undetectable levels within 8-10 h of exposure (Fig. 6 ). Liver concentrations were below detection limits in the 0.3-mg/kg dose group. The model accurately simulated peak liver concentrations of deltamethrin as well as the rapid decline in tissue concentrations (Fig. 6) . The rapid decline of deltamethrin concentrations in the liver is consistent with its rapid metabolism in this tissue (Godin et al., 2006; Mirfazaelian et al., 2006) .
Simulation of Fat Concentrations after Po Exposure
Fat concentrations of deltamethrin were determined out to 48 h after po exposures of 0.3 and 3.0 mg/kg. Fat concentrations of deltamethrin peaked within 8 h of initial exposure and remained at this level throughout the time period monitored (Fig. 7) . The model accurately simulated the concentration-time curves at both doses (Fig. 7) .
Simulation of Literature Data
PBPK model simulations were compared to available literature data on deltamethrin tissue concentrations obtained by Gray and Rickard (1982) (Figs. 4 and 8) , Mirfazaelian et al. (2006) (Fig. 9) , and Ruzo et al. (1978) (Fig. 10 ). Gray and Rickard (1982) exposed animals to 1.75 mg/kg deltamethrin iv and followed blood concentrations over 4 h postdosing. The blood concentration data of Gray and Rickard (1982) display a biphasic distribution over the first 4 h. This biphasic clearance is similar to that seen in the current study and is accurately described by the model (Fig. 4) . Gray and Rickard (1982) also reported concentrations of deltamethrin in three different regions of the brain with very little variability between regions. Figure 8 depicts model simulations compared to the average brain concentration of deltamethrin from Gray and Rickard (1982) . The model simulations of brain concentrations compared very well with these data (Fig. 8) . The brain data, similar to the blood data, have a biphasic time course, which was also described well by the model.
Simulation of blood concentrations following po exposures by the present model resulted in good agreement with the data from Mirfazaelian et al. (2006) (Figs. 9B and 9C ). However, there were some inconsistencies in simulations of the data of Mirfazaelian et al. (2006) by the present model. The model underestimated the brain concentrations at the later time points (12 and 24 h) for the 10-mg/kg dose from Mirfazaelian et al. (2006) .
The fat concentration data from the present study and Mirfazaelian et al. (2006) are similar up to the last time point (48 h) examined in the present study. The data of Mirfazaelian et al. (2006) , however, include time points at 336 and 504 h. The initial optimized fat P T resulted in underestimates of the fat concentrations at these later time points. Inclusion of these data in the formal optimization does not result in significant changes to the P T , and the model still underestimated the fat concentrations at the later time points. This discrepancy appears to be due, in part, to the greater weighting of the more plentiful data from the early time points in the optimization routine. Alternatively, this discrepancy may indicate that the fat compartment may not be modeled adequately. However, by 
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visually adjusting the fat P T and PA T C, the model adequately approximates the fat time course data in rats. Model simulations of data from the present study using the computationally derived fat P T were similar to model simulations using the visually optimized P T for fat (Fig. 7) . Optimization decreased the computationally derived fat P T by a factor of five.
However, the use of either value resulted in fits consistent with the data up to 48 h postexposure. Ruzo et al. (1978) reported tissue residues of deltamethrin in the fat at 8 days (192 h) postoral dosing at three different dose levels. The visually optimized diffusion-limited model resulted in good agreement with these data (Fig. 10) . This further increases confidence in the visually optimized fat partition and PA T C determined with the data of Mirfazaelian et al. (2006) .
Human Modeling
Extrapolation of the model to humans used human physiological parameters from Brown et al. (1997) and metabolic parameters from Godin et al. (2006) (Table 1) . Data from controlled human exposure to deltamethrin are limited to an po absorption study in three healthy volunteers conducted by Roussel-Uclaf in 1984 (Papalexiou et al., 1984) . Volunteers were given a single 3-mg (% 0.43 mg/kg) po dose of 14 C-labeled deltamethrin in a 10-ml suspension of poly (oxyethylene glycol)-300 and diluted with water to a final volume of 150 ml. Total radioactivity in the blood, urine, and feces was reported over 96 h postexposure. This limits the use of these data since the radioactivity in blood and excreta could be from the parent compound, its metabolites, or both parent and metabolites. The radioactivity found in the blood is likely not all deltamethrin, and the inability to discriminate between parent and metabolites in the feces does not allow evaluation of the absorption parameters in the human model. Cumulative urinary excretion of radioactivity averaged 48 ± 3% of the po dose after 96 h. Cumulative fecal excretion averaged 17 ± 8%, with a range of 10-25%, of the administered dose after 72 h. This range is within literature values for fecal excretion in rats (Bosch 1990; Cole et al., 1982; Crawford et al., 1981a,b; Ruzo et al., 1978) . However, based on the limited number of subjects and the use of total radioactivity as a measure of dose, there are uncertainties in directly comparing the fecal excretion in the human study to the rat studies.
The cumulative urinary and fecal excretion in the human study accounts for~65% of the total radioactivity of the administered dose. In rats administered pyrethroids, only hydrolyzed metabolites of pyrethroids are present in the urine, while the feces contains predominately parent chemical, with minor amounts of hydroxylated metabolites (Bosch 1990; Cole et al., 1982; Crawford et al., 1981a,b; Ruzo et al., 1978) . Thus, the radioactivity in the urine from the human study is hypothesized to be primarily deltamethrin metabolites. Therefore, the percentage of the administered dose metabolized in the human PBPK model may be used as a surrogate to compare to the human urinary excretion data. The human PBPK model predicted 66% of an po dose was metabolized over 96 h compared with 48% of the radioactive dose observed in the Roussel-Uclaf study.
In rats, 1.0 mg/kg deltamethrin is approximately a threshold dose for changes in motor activity (Wolansky et al., 2006) . Similarly, the no observable adverse effect level of deltamethrin used for the reference dose by the U.S. Environmental Protection Agency is 1.0 mg/kg/day based on an acute neurotoxicity study in rats (Crofton et al., 1995) and a 1-year chronic toxicity study in dogs (Federal Register, 2004) . Simulation of brain concentrations following a single po exposure of 1 mg/kg deltamethrin using the rat and human model resulted in similar predicted peak concentrations in rats and humans (Fig. 11) . Concentrations of deltamethrin in the brain were predicted to peak in the rat at~2.5 h while human peak brain concentrations were predicted to occur at 3.5 h. The model predicted a twofold greater peak deltamethrin concentration for humans than rats. The AUC 0-48 h for the predicted human brain concentration of deltamethrin is about three times greater than the AUC 0-48 h for the rat brain concentration.
Sensitivity Analysis
Sensitivity analysis was conducted on the rat and human models. Table 2 presents the NSCs for each parameter in both the rat and the human models. The rat and human models were most sensitive to liver blood flow (QLC) and the diffusion limitation (PA L C). Hepatic clearance was diffusion limited, so the metabolic clearance parameter (K cl ) was not a sensitive parameter.
Absorption parameters were also relatively sensitive. Fecal excretion (K fe ), when increased, decreased peak blood and brain concentrations by reducing the amount of deltamethrin absorbed into the systemic circulation. Conversely, increases in K i and the stomach-intestine transfer rate constant (K si ), which describe the transfer and uptake of deltamethrin through the GI compartment, resulted in increases in peak blood concentrations due to more rapid and greater deltamethrin absorption. Partitioning (P Br ) and the diffusion limitation (PA Br C) in the brain impact peak brain concentration but have no significant effect on blood concentrations. 
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describes the liver as a flow-limited compartment. However, there were no deltamethrin liver concentration data available to evaluate this assumption. In order to resolve ambiguities in absorption and distribution data in the literature, the present study examined the bioavailability of deltamethrin and determined liver concentrations of deltamethrin following po exposures. These data provided the basis of modifying the Mirfazaelian model, which resulted in more accurate model simulations across more data sets.
Bioavailability of deltamethrin was examined at two doses. One dose (3.0 mg/kg) was at the approximate effective dose 30 for decreases in motor activity (Wolansky et al., 2006) and a second dose 10-fold lower (0.3 mg/kg) where minimal po absorption is predicted by the Mirfazaelian et al. (2006) model. The results indicate that there was no difference in the po bioavailability of deltamethrin at these doses. Bioavailability of deltamethrin was higher in this work as compared to previous reports by Anadon et al. (1996) and Kim et al. (2007 Kim et al. ( , 2008 , which reported~15-18% bioavailability at po doses ranging from 2 to 26 mg/kg. This difference is likely due to different experimental protocols such as choice of vehicles and dosing volumes. Crofton et al. (1995) found that increasing dosing volume decreases the potency of deltamethrin and that the choice of vehicle can alter the potency of deltamethrin by over an order of magnitude. Bifenthrin administered to rats by po gavage was about twofold more potent at 1 than 5 ml/kg in affecting motor activity and other neurotoxic end points (Wolansky et al., 2007) . Both Anadon et al. (1996) and Kim et al. (2007 Kim et al. ( , 2008 used a greater dosing volume and different vehicles than used in the present study, which may account for the differences in bioavailability of deltamethrin.
The results of the bioavailability study do not indicate a dose-dependent po absorption of deltamethrin, even at a dose that the Mirfazaelian model predicts to be poorly absorbed. These results are consistent with all the available data on either fecal elimination (Fig. 1) or po bioavailability of deltamethrin. Thus, the description of po absorption in the present model was simplified and based on the PBPK model for chlorpyrifos by Timchalk et al. (2002) .
Another departure from the Mirfazaelian model was the use of diffusion-limited kinetics in all tissue compartments. The clearest evidence supporting a diffusion-limited description of deltamethrin was found in the ability of the diffusion-limited model to describe the shape of the blood concentration-time curves after iv dosing. In the present study and that of Gray and Rickard (1982) , iv administration of deltamethrin resulted in a biphasic distribution of deltamethrin in the blood within a few hours of exposure (Figs. 3A inset and 4). This was accurately described by the diffusion-limited model in contrast to the model of Mirfazaelian et al. (2006) . The diffusion-limited model was also able to describe the shape of the brain concentration versus time curve (Gray and Rickard, 1982) (Fig. 8) . The brain, like the blood, displayed a biphasic distribution that was accurately depicted by the diffusionlimited model. While other model structures, such as incorporation of flow-limited compartments, may be able to provide adequate descriptions of some deltamethrin tissue concentration-time curves (Mirfazaelian et al., 2006) , they do not appear to accurately describe the rapid changes in tissue concentrations after an iv dose.
Diffusion limitation in the liver reduces the rate at which a chemical enters and exits a tissue compartment. Comparisons of liver concentrations to model predictions indicate that the diffusion-limited model accurately described the rapid decrease in liver concentrations of deltamethrin (Fig. 6) . The use of a diffusion-limited description of the liver allows for the incorporation of the in vitro hepatic clearance values of Godin et al. (2006) without attenuation, which is necessary when using the flow-limited description of the liver.
The target tissue for pyrethroid neurotoxicity is the central nervous system (Rickard and Brodie 1985) . Accurate prediction of brain concentrations is therefore central to the utility of this model. The diffusion-limited model accurately simulated brain concentration-time course data from a 3.0-mg/kg po dose in this study and after a 1.75-mg/kg iv dose (Gray and Rickard 1982) . However, this model did not accurately simulate the brain concentration-time curves at the 10 mg/kg (Fig. 9) indicate that concentrations in the brain remain elevated out to 24 h. It is difficult to assess why there are differences between the present study and those of Mirfazaelian et al. (2006) . However, neurobehavioral studies of deltamethrin in rats indicate that the greatest decrease in motor activity occur around 2 h postexposure and the motor activity returns to control levels by 4 h (Crofton and Reiter, 1984) . The behavioral time course corresponds well with the time of peak brain concentrations in the present study and that simulated by the current model. Our modeling efforts utilized computational methods to estimate P T for the different tissues of the body. The computationally derived parameters were very near optimized values in tissue compartments except for the fat and brain (Table 1 ). The discrepancies between computational and optimized values in the brain and adipose tissue may be due to either the limitation of the computational methods or to unidentified biological processes that regulate the distribution of deltamethrin to these tissues. This issue was also described by Mirfazaelian et al. (2006) who also presented similar findings for a number of other highly lipophilic chemicals. In the brain, there may be thermodynamic limitations of the compound crossing the blood-brain barrier resulting in a permeability-limited process. The method of Poulin and Theil (2000) does not apply to chemicals for which a permeabilitylimited process is involved. One explanation of the much lower optimized brain P T is that a permeability-limited process is involved for getting deltamethrin across the blood-brain barrier. Alternatively, deltamethrin may potentially interact with transporters at the blood-brain barrier, reducing the ability of deltamethrin to distribute into this organ. Future studies examining the interaction of deltamethrin and efflux transporters are warranted.
It is difficult to determine why discrepancies between the computationally derived fat P T and the optimized value necessary to fit the available fat data exist. The computational value appears to fit peak fat concentrations of deltamethrin (Fig. 7) and allows accurate estimation of other tissue concentration profiles (Figs. 3-9 ) because there is little discrepancy between its estimation with that of the optimized value within the first 48 h (Fig. 7) . However, the computational value predicts that deltamethrin fat concentrations remain elevated for considerably longer than literature data suggest. It is currently unknown why the deltamethrin fat P T had to be lowered fourfold for such a highly lipophilic chemical. Other modeling attempts utilizing these computational approaches for highly lipophilic compounds, such as dioxin, have also overestimated P T necessary to describe the data (Emond et al., 2004 (Emond et al., , 2005 .
The discrepancy index of Krishnan et al. (1995) was utilized to compare model modifications and structures (see Supplementary data, Table 1 ). Modifications to the Mirfazaelian model to render it more parsimonious resulted in a nominally equivalent model, which resulted in a lower discrepancy index of 50% compared to the experimental data. The diffusionlimited model resulted in the lowest discrepancy index, indicating that this model structure was a more appropriate description of the pharmacokinetics of deltamethrin than that of a flow-limited model.
The rat model was used as the basis for developing a human deltamethrin PBPK model. The rat and human models were then used to simulate a 1-mg/kg po exposure, which is the threshold dose for decreases in motor activity in rats. Predictions obtained with the present model indicate that a 1-mg/kg exposure results in twofold greater peak brain concentrations for humans. The model also predicts that the AUC (0-48 h) in humans will be approximately threefold greater. We applied the same rate constant for po absorption of deltamethrin in humans and rats under the assumption that po absorption occurs by passive diffusion. However, if uptake was mediated by an energy-dependent process, such as active transport, the rate constant would scale allometrically. Savage et al. (2004) reported that there is a substantial body of literature indicating that physiological rates closely related to use of energy scale according to kilogram À1/4 . With quarterpower scaling the peak concentration would be the same in humans and rats following a dose of 1 mg/kg but would be delayed in humans from 3.5 to about 6 h. In addition, allometric scaling of the po absorption results in a twofold greater AUC (0-48 h) in humans (opposed to threefold under the passive model); thus, quarter-power allometric scaling is slightly anticonservative. The impact of allometric scaling of po absorption is illustrated in the Supplementary data. Given the lack of compelling evidence for an active transport process mediating po absorption, we proposed and applied the slightly more conservative passive diffusion model that maintains the same rate constant. Thus, using the passive diffusion model and depending on the choice of dose metric, humans may have a twofold (peak) or threefold (AUC 0-48 h ) greater response for a given exposure than rats. Further investigation into which dose metric best predicts the neurotoxicity of pyrethroids would be valuable in resolving this uncertainty.
Another uncertainty in the species differences in the pharmacokinetics of deltamethrin is the importance of cardiac output to the brain. The differences in the AUC and peak brain concentrations between the rat and human models are likely influenced by differences in the cardiac output to the brain. In humans, the cardiac output to the brain is almost six times higher than rodents. These parameters are equally sensitive in the rat and human model, and increasing this parameter in humans may result in greater brain concentrations. It should be noted that, while humans may have greater brain concentrations, this does not necessarily imply greater sensitivity to the toxic effects of deltamethrin. The sensitivity of humans to deltamethrin involves not only pharmacokinetic properties but also pharmacodynamic 340 properties as well. The present study only examined the potential species differences in the pharmacokinetics of deltamethrin and does not demonstrate that humans are more sensitive to the toxic effects of this chemical.
Model structure can have a significant impact on the risk assessment of pyrethroids. A diffusion-limited model such as the one presented here minimizes the effect of the species difference in metabolism of deltamethrin (Godin et al., 2006) . In a diffusion-limited description of the liver, the rate-limiting step in the elimination of deltamethrin is not the clearance rate but rather the rate of diffusion of compound from blood into tissue. Diffusion-limited kinetics would also have the effect of reducing the impact of interindividual differences in the capacity for metabolism of deltamethrin in the human population. One of the limitations of applying this model for risk assessments would be the description of the distribution of deltamethrin to the brain. Further research in this area is needed to better identify mechanisms for the lower than expected brain concentrations in rats. Understanding this process would enhance our confidence in the model predictions of target tissue concentrations.
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